

Supplementary Table 1. Use of antidiabetic agents in participants from 2002 to the time of the examination ($n=470$)

Antidiabetic drug use	No. (%) ^a	Duration, mo ^b
Metformin	344 (73.2)	74.3 (34.8–111.6)
Sulfonylurea	222 (47.2)	55.8 (15.2–111.9)
Glinide	19 (4.0)	9.2 (2.1–62.9)
GLP-1R agonist	8 (1.7)	6.7 (1.8–25.8)
DPP-4 inhibitor	203 (43.2)	54.6 (17.0–74.6)
TZD	136 (28.9)	43.2 (14.7–61.9)
SGLT2 inhibitor	135 (28.7)	25.5 (9.1–47.3)
AGI	33 (7.0)	42.2 (5.3–61.1)
Insulin	5 (1.1)	4.0 (3.1–6.4)

GLP-1R, glucagon-like peptide-1 receptor; DPP-4, dipeptidyl peptidase-4; TZD, thiazolidinedione; SGLT2, sodium-glucose cotransporter 2; AGI, alpha-glucosidase inhibitor.

^aNumber of participants who received antidiabetic agents at least once, ^bMedian duration (interquartile range) of antidiabetic drug use among participants receiving the drug.